Outcome of Board Meeting

August 5, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Outcome of the Board Meeting held on August 5, 2026 The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. b) a proposal to file a Scheme of Amalgamation for merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited, wholly owned step-down subsidiaries of the Company with Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company, with Hon’ble NCLT, Hyderabad, that has been approved by the Board of Directors of the respective companies and also the Company. The Board meeting commenced at 4:00 p.m. and concluded at 6.30 p.m. Please take the information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: as above. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com AUROBINDO PHARMA LIMITED (CIN -L24239TG1986PLC015190) www aurobindo.com Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad -500 038, India Tel: +91 (40) 66721200; Fax: +9140 23741080; Email: info@aurobindo.com (All amounts are in ~ million, unless otherwise stated) STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Quarter ended Year ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Unaudited Unaudited Unaudited Audited (Refer note 7l 1 Revenue from operations (a) Net sales/ income from operations 27,816.9 27,469.8 28,22l.4 1,10,553.9 (b) Other operating income 178.2 395.7 260.3 1,163.3 Total revenue from operations 27,995.1 27,865.5 28,481.7 1,11,717.2 2 Other income (a) Foreign exchange gain (net) 729.9 203.5 406.0 1,790.7 (b) Others 1,689.0 1,937.4 431.7 4,084.6 Total other income 2,418.9 2,140.9 837.7 5,875.3 3 Total income (1+2) 30,414.0 30,006.4 29,319.4 1,17,592.5 4 Expenses (a) Cost of materials consumed 12,888.9 12,516.6 13,400.1 52,383.8 (b) Purchase of stock-in-trade 165.2 143.8 732.0 (c) Changes in inventories of finished goods, stock-in-trade and (480.5) 427.9 384.8 465.5 work-in-progress (d) Employee benefits expense 2,959.1 2,927.1 2,829.7 11,611.5 (e) Finance costs 470.7 472.7 600.0 2,131.5 (f) Depreciation and amortisation expenses 689.9 719.3 700.2 2,853.6 (g) Other expenses 3,805.1 4,014.5 3,759.9 15,605.0 Total expenses 20,333.2 21,243.3 21,818.5 85,782.9 5 Profit before exceptional items and tax (3-4) 10,080.8 8,763.1 7,500.9 31,809.6 6 Exceptional items (refer note 4) - - 173.8 7 Profit before tax (5-6) 10,080.8 8,763.1 7,500.9 31,635.8 8 Tax expense Current tax 2,715.0 1,819.5 1,876.8 7,468.2 Deferred tax (6.4) 21.3 32.8 19.6 Total tax expense 2,708.6 1,840.8 1,909.6 7,487.8 9 Profit after tax (7-8) 7,372.2 6,922.3 5,591.3 24,148.0 10 Other comprehensive income Items that will not to be reclassified subsequently to profit or loss: (a) Re-measurement of defined benefit liability 3.6 48.4 (17.6) 14.5 (b) Income-tax relating to items that will not be reclassified to profit (0.9) (12.2) 4.4 (3.7) or loss Total other comprehensive income/(Ioss) (net of tax) 2.7 36.2 (13.2) 10.8 11 Total comprehensive income (9+10) 7,374.9 6,958.5 5,578.1 24,158.8 12 Paid-up equity share capital (face value ~ 1 per share) 575.4 580.8 580.8 580.8 13 O't her eq u ltv 2,26,596.1 14 Earnings per equity share (face value ~ 1 per share) (Not annualised (Not annualised) (Not annualised) (Annualised) (a) Basic (In ~) 12.75 1l.92 9.63 41.58 b) Diluted (In ~) 12.75 11.92 9.63 41.58 Page 1 of 2 NOTES: 1 The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2 The above unaudited standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on August OS, 2026. The results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2026. 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment". 4 During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company assessed the implications of the New Labour Codes and recognized an incremental cost of ~ 173.8 million during the year ended March 31, 2026. 5 The Board of Directors of Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ~ 1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding ~ 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of ~ 1,475 per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations. Consequently, the paid-up equity share capital has been reduced by ~ 5.4 million. The aggregate amount paid for buyback is ~ 8,065.3 million including related expenses. 6 The Board of Directors of the Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026. Accordingly, the net assets of the business have been transferred at the consideration of ~ 1,432.1 Million to Auropharm Limited. 7 The figures for the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and published year to date figures up to third quarter ended December 31, 2025 and which were subject to limited review by the statutory auditors. By Order of the Board For Aurobindo Pharma Lim [Showing first 8,000 characters — download PDF for full document]